Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress In the panel sessions, Dr David Roblin, Chief Operating Officer and President of R&D, Dr Richard Vickers, Chief Scientific Officer, and Dr David Powell, Head of Research, will high...... 12:00 GMT Wednesday 6th November 2019
Summit Therapeutics Recognises C. difficile Awareness Month As part of its activities for CDI awareness month, Summit will be presenting at the 7 Annual Conference and Health EXPO in St. Louis, Missouri. The presentation will review data f...... 12:00 GMT Monday 4th November 2019
Summit Therapeutics to Present at the 2019 BIO Investor Forum A live webcast of the presentation will be available in the Investors section of the Company's website, . A replay of the webcast will be available from the same location soon afte...... 12:00 GMT Wednesday 16th October 2019
Directorate change This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).-END-...... 12:01 GMT Friday 11th October 2019
Half-year report This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).Other operating income was £4.1 million for the three months ended 31 ...... 12:00 GMT Friday 11th October 2019
Notice of Results Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release,...... 14:30 GMT Thursday 10th October 2019
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Researchers at Tufts University, collaborating with Summit, showed that these findings are connected mechanistically by bile acids, part of the ‘metabolome’ of active chemicals...... 12:00 GMT Monday 7th October 2019
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care The Phase 2 clinical trial called CoDIFy evaluated ridinilazole compared to vancomycin in 100 patients with CDI. As part of the trial, patients completed the EuroQol 5-Dimension qu...... 12:00 GMT Thursday 3rd October 2019
Block Listing Six Month Review (Note: Italicised terms have the same meaning as given in the Listing Rules.)...... 07:00 GMT Thursday 3rd October 2019
Summit Therapeutics to Host R&D Day 7 October 2019 The event will feature leading experts: Dr Casey Theriot, of North Carolina State University, on the role of the microbiome in infection (‘CDI’) and Dr Kevin Garey, of the Uni...... 12:00 GMT Wednesday 25th September 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.